The COVID-19 pandemic forced investigators conducting clinical trials to use decentralized elements, such as telehealth, to continue their research.
The FDA provided recommendations to investigators during the pandemic about how to integrate decentralized elements into clinical trials. Last fall, the agency issued guidance for the continued use of these elements, ensuring their role in trials for the foreseeable future.
“It’s hard to tell everybody to reverse course, especially because of the benefits that they bring to patients and sites who are conducting the trial,” Joseph